Long Term, Open-Label, Safety Follow Up Study Following Transplantation of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)) in Subjects with Acute Wet Age Related Macular Degeneration and Recent Rapid Vision Decline
Latest Information Update: 26 Nov 2024
At a glance
- Drugs PF 5206388 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 22 Nov 2024 Planned End Date changed from 30 May 2033 to 30 Jun 2028.
- 22 Nov 2024 Planned primary completion date changed from 30 May 2033 to 30 May 2027.
- 22 Nov 2024 Status changed from not yet recruiting to active, no longer recruiting.